Lymphomaswithconcurrent BCL and MYC…淋巴瘤并发和.pdfVIP

From by guest on February 24, 2016. For personal use only. LYMPHOID NEOPLASIA Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival 1,2 3 1 1,2 4 1,2 Nathalie A. Johnson, Kerry J. Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, 5 6 3 3 3 1,2 Martin J. S. Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa, Joseph M. Connors, Randy D. Gascoyne, and 1,2 Douglas E. Horsman 1Department of Pathology, 2Center for Translational and Applied Genomics, and Departments of 3Medical Oncology and 4 Population Oncology, British Columbia Cancer Agency, Vancouver, BC; 5Medical Research Council Toxicology Unit/University of Leicester, Leicester, United Kingdom; and 6 Institute of Human Genetics, Christian-Albrechts-University Kiel University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany BCL2 and MYC are oncogenes commonly presence of a t(14;18), 5 cases were BCL2 treatment with rituximab-based chemo- deregulated in lymphomas. Concurrent protein–negative. Nonimmunoglobulin gene/ therapy, were associated with a more BCL2 and MYC translocations (BCL2 MYC (non-IG/MYC) translocations occurred favorable outcome, but a low Interna- / MYC) were identified in 54 samples by in 24 of 54 cases (44%) and were highly tional Prognostic Index score and DLBCL karyotype and/or fluorescence in situ hybrid- associ